Cantor Fitzgerald Comments on MannKind FY2026 Earnings

MannKind Co. (NASDAQ:MNKD - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of MannKind in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings of $0.24 per share for the year. The consensus estimate for MannKind's current full-year earnings is $0.10 per share.

MannKind (NASDAQ:MNKD - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. The company had revenue of $78.35 million during the quarter, compared to analyst estimates of $75.86 million. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. MannKind's quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.05 earnings per share.

Several other equities analysts have also weighed in on the stock. Wall Street Zen lowered shares of MannKind from a "buy" rating to a "hold" rating in a research report on Friday, June 6th. Wedbush reissued an "outperform" rating and set a $11.00 target price on shares of MannKind in a research report on Thursday, February 27th. Finally, Mizuho started coverage on shares of MannKind in a research note on Thursday, April 10th. They set an "outperform" rating and a $12.00 price target for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, MannKind currently has an average rating of "Buy" and a consensus target price of $10.00.

MannKind Price Performance

Shares of NASDAQ MNKD traded down $0.12 during mid-day trading on Tuesday, reaching $3.71. 1,780,690 shares of the company's stock were exchanged, compared to its average volume of 2,386,423. The firm has a 50-day moving average price of $4.48 and a two-hundred day moving average price of $5.37. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of 53.00 and a beta of 1.02. MannKind has a 52 week low of $3.71 and a 52 week high of $7.63.

Institutional Trading of MannKind

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. E Fund Management Co. Ltd. boosted its stake in MannKind by 9.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 22,039 shares of the biopharmaceutical company's stock worth $142,000 after purchasing an additional 1,828 shares during the period. Xponance Inc. lifted its holdings in shares of MannKind by 10.6% in the fourth quarter. Xponance Inc. now owns 19,067 shares of the biopharmaceutical company's stock worth $123,000 after buying an additional 1,828 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of MannKind by 4.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 60,895 shares of the biopharmaceutical company's stock valued at $306,000 after acquiring an additional 2,420 shares during the period. Summit Investment Advisors Inc. grew its stake in MannKind by 10.4% during the fourth quarter. Summit Investment Advisors Inc. now owns 28,174 shares of the biopharmaceutical company's stock valued at $181,000 after acquiring an additional 2,657 shares in the last quarter. Finally, AXQ Capital LP increased its holdings in MannKind by 19.8% during the 4th quarter. AXQ Capital LP now owns 22,530 shares of the biopharmaceutical company's stock worth $145,000 after acquiring an additional 3,717 shares during the period. 49.55% of the stock is currently owned by institutional investors.

Insider Transactions at MannKind

In related news, Director Steven B. Binder sold 80,144 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $4.69, for a total transaction of $375,875.36. Following the sale, the director now directly owns 1,006,611 shares in the company, valued at approximately $4,721,005.59. This represents a 7.37% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP David Thomson sold 32,179 shares of MannKind stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $4.68, for a total transaction of $150,597.72. Following the completion of the transaction, the executive vice president now owns 772,427 shares of the company's stock, valued at $3,614,958.36. This represents a 4.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 190,831 shares of company stock worth $846,298 over the last quarter. Corporate insiders own 2.70% of the company's stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.